Fibrogen Inc CS (FGEN)

Dec 16, 2024, 8:05 AM EST - 4 weeks ago

FibroGen Appoints David DeLucia as Chief Financial Officer

Nov 12, 2024, 8:38 PM EST - 2 months ago

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

Nov 12, 2024, 4:05 PM EST - 2 months ago

FibroGen Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 2 months ago

FibroGen to Report Third Quarter 2024 Financial Results

Aug 9, 2024, 11:32 AM EDT - 5 months ago

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 12:33 PM EDT - 6 months ago

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

Jul 30, 2024, 4:07 PM EDT - 6 months ago

FibroGen to Report Second Quarter 2024 Financial Results

Jun 6, 2024, 12:38 PM EDT - 8 months ago

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 3, 2024, 4:05 PM EDT - 8 months ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:02 PM EDT - 8 months ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

May 23, 2024, 5:05 PM EDT - 8 months ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 7, 2024, 7:00 AM EDT - 9 months ago

FibroGen to Participate in Upcoming Investor Conferences

May 6, 2024, 10:31 PM EDT - 9 months ago

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

May 6, 2024, 4:02 PM EDT - 9 months ago

FibroGen Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 9 months ago

FibroGen to Report First Quarter 2024 Financial Results

Apr 24, 2024, 4:02 PM EDT - 9 months ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 2, 2024, 5:46 PM EDT - 10 months ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Mar 26, 2024, 7:00 AM EDT - 10 months ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 7:00 AM EDT - 11 months ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Feb 26, 2024, 11:44 PM EST - 11 months ago

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:18 PM EST - 11 months ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

Feb 26, 2024, 4:06 PM EST - 11 months ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 11 months ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 20, 2024, 7:00 AM EST - 11 months ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 5, 2024, 7:00 AM EST - 1 year ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Jan 25, 2024, 7:00 AM EST - 1 year ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Dec 9, 2023, 5:02 PM EST - 1 year ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Nov 6, 2023, 8:30 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 4:01 PM EST - 1 year ago

FibroGen Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 1 year ago

FibroGen to Report Third Quarter 2023 Financial Results

Sep 27, 2023, 1:00 PM EDT - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Aug 30, 2023, 7:55 AM EDT - 1 year ago

FibroGen shares fall after failure in late-stage study of Duchenne muscular dystrophy treatment

Aug 29, 2023, 4:15 PM EDT - 1 year ago

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

Aug 29, 2023, 5:00 AM EDT - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

Aug 7, 2023, 10:10 PM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 4:01 PM EDT - 1 year ago

FibroGen Reports Second Quarter 2023 Financial Results

Jul 25, 2023, 7:00 AM EDT - 1 year ago

FibroGen Announces Leadership Transition

Jul 24, 2023, 7:00 AM EDT - 1 year ago

FibroGen to Report Second Quarter 2023 Financial Results

Jul 18, 2023, 8:54 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me

AADI INGN SILK THRX

Jul 8, 2023, 7:00 AM EDT - 1 year ago

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Jul 3, 2023, 1:00 AM EDT - 1 year ago

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm

Jun 27, 2023, 9:00 AM EDT - 1 year ago

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Fibrogen, Inc. and Encourages Investors With Losses to Contact the Firm